Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$22.03 -1.4%	$17.84	$9.57 ▼ $27.34	$3.05B	1	2.48 million shs	2.39 million shs
IOVA Iovance Biotherapeutics	$2.23	$2.34	$1.64 ▼ $12.51	$806.93M	0.82	14.88 million shs	7.02 million shs
SRRK Scholar Rock	$32.65 -1.9%	$35.65	$6.76 ▼ $46.98	$3.14B	0.36	1.98 million shs	1.42 million shs
VKTX Viking Therapeutics	$27.05 -1.9%	$31.24	$18.92 ▼ $81.73	$3.04B	0.73	9.77 million shs	3.79 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	+3.28%	+38.29%	+34.33%	-7.55%
IOVA Iovance Biotherapeutics	0.00%	-17.10%	-16.79%	+26.70%	-80.87%
SRRK Scholar Rock	0.00%	-8.00%	-10.20%	+9.71%	+251.08%
VKTX Viking Therapeutics	0.00%	+4.04%	-17.23%	+3.56%	-57.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.6719 of 5 stars	3.5	1.0	3.4	3.0	2.5	0.0
IOVA Iovance Biotherapeutics	4.6876 of 5 stars	4.2	4.0	4.2	1.6	2.5	1.3
SRRK Scholar Rock	4.4301 of 5 stars	4.6	0.0	4.4	2.5	3.3	0.6
VKTX Viking Therapeutics	3.9742 of 5 stars	3.5	1.0	4.7	3.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	3.00	Buy	$43.14	95.84% Upside
IOVA Iovance Biotherapeutics	2.36	Hold	$11.90	433.63% Upside
SRRK Scholar Rock	3.20	Buy	$45.75	40.12% Upside
VKTX Viking Therapeutics	3.00	Buy	$86.92	221.34% Upside

Current Analyst Ratings Breakdown

Latest IOVA, SRRK, ARWR, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	SRRK Scholar Rock	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$50.00
8/19/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/19/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
8/12/2025	IOVA Iovance Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/11/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/8/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$40.00 ➝ $38.00
8/8/2025	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$18.00 ➝ $14.00
8/8/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
8/7/2025	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $45.00
7/30/2025	SRRK Scholar Rock	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Strong-Buy	$53.00

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	857.99	N/A	N/A	$1.54 per share	14.31
IOVA Iovance Biotherapeutics	$164.07M	4.92	N/A	N/A	$2.33 per share	0.96
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$3.94 per share	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.28	N/A	N/A	N/A	N/A	-40.91%	-11.62%	N/A
IOVA Iovance Biotherapeutics	-$372.18M	-$1.23	N/A	N/A	N/A	-161.44%	-52.87%	-41.31%	11/6/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.91	N/A	N/A	N/A	N/A	-127.11%	-90.09%	11/11/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.53	N/A	N/A	N/A	N/A	-19.98%	-19.38%	10/22/2025 (Estimated)

Latest IOVA, SRRK, ARWR, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	-$1.26	-$0.32	-$1.26	$29.01 million	$27.77 million
8/7/2025	Q2 2025	IOVA Iovance Biotherapeutics	-$0.29	-$0.33	-$0.04	-$0.33	$67.14 million	$59.95 million
8/6/2025	Q2 2025	SRRK Scholar Rock	-$0.66	-$0.98	-$0.32	-$0.98	$0.11 million	N/A
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	-$0.58	-$0.14	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.39	4.87	4.87
IOVA Iovance Biotherapeutics	N/A	3.27	2.89
SRRK Scholar Rock	0.21	6.33	6.33
VKTX Viking Therapeutics	N/A	25.86	25.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
IOVA Iovance Biotherapeutics	77.03%
SRRK Scholar Rock	91.08%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
IOVA Iovance Biotherapeutics	10.30%
SRRK Scholar Rock	13.30%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.26 million	132.31 million	Optionable
IOVA Iovance Biotherapeutics	500	361.85 million	324.58 million	Optionable
SRRK Scholar Rock	140	96.13 million	83.34 million	Optionable
VKTX Viking Therapeutics	20	112.44 million	107.84 million	Optionable

IOVA, SRRK, ARWR, and VKTX Headlines

Recent News About These Companies

FORA Capital LLC Has $268,000 Stock Holdings in Viking Therapeutics, Inc. $VKTX

September 1 at 4:43 AM | marketbeat.com

Invesco Ltd. Sells 787,865 Shares of Viking Therapeutics, Inc. $VKTX

September 1 at 3:31 AM | marketbeat.com

Rafferty Asset Management LLC Sells 87,394 Shares of Viking Therapeutics, Inc. $VKTX

August 31 at 5:22 AM | marketbeat.com

AlphaQuest LLC Acquires 9,815 Shares of Viking Therapeutics, Inc. $VKTX

August 31 at 4:26 AM | marketbeat.com

Raymond James Financial Inc. Buys 28,922 Shares of Viking Therapeutics, Inc. $VKTX

August 31 at 3:37 AM | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights

August 29 at 6:46 PM | zacks.com

Viking Therapeutics to Participate at Upcoming Investor Conferences

August 28, 2025 | prnewswire.com

Affinity Asset Advisors LLC Acquires Shares of 25,000 Viking Therapeutics, Inc. $VKTX

August 28, 2025 | marketbeat.com

Viking Therapeutics, Inc. $VKTX Shares Sold by Russell Investments Group Ltd.

August 28, 2025 | marketbeat.com

Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?

August 27, 2025 | zacks.com

Nuveen LLC Buys Shares of 384,379 Viking Therapeutics, Inc. $VKTX

August 26, 2025 | marketbeat.com

Short Report: Viking Therapeutics short interest at 5-year high after VK273 data

August 25, 2025 | msn.com

Viking Therapeutics, Inc. $VKTX Shares Sold by Charles Schwab Investment Management Inc.

August 25, 2025 | marketbeat.com

2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts

August 24, 2025 | fool.com

Is Viking Therapeutics stock a bargain after this week’s sell-off?

August 23, 2025 | msn.com

Analysts Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Price Target at $86.92

August 23, 2025 | americanbankingnews.com

Viking Therapeutics (VKTX) Down 23.4% Since Last Earnings Report: Can It Rebound?

August 22, 2025 | msn.com

Viking Therapeutics (VKTX) Reports Increased Net Losses For Second Quarter

August 22, 2025 | finance.yahoo.com

Here's Why Shares in Viking Therapeutics Crashed This Week

August 22, 2025 | msn.com

Viking Therapeutics (VKTX) Rebounds on Bargain-Hunting. Are You Missing Out?

August 21, 2025 | insidermonkey.com

A Closer Look at Viking Therapeutics's Options Market Dynamics

August 21, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, SRRK, ARWR, and VKTX Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$22.03 -0.31 (-1.39%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$22.58 +0.56 (+2.52%)

As of 08/29/2025 07:59 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Iovance Biotherapeutics NASDAQ:IOVA

$2.23 0.00 (0.00%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.25 +0.02 (+0.90%)

As of 08/29/2025 07:57 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Scholar Rock NASDAQ:SRRK

$32.65 -0.63 (-1.89%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$32.65 0.00 (0.00%)

As of 08/29/2025 05:58 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$27.05 -0.53 (-1.92%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$27.14 +0.09 (+0.31%)

As of 08/29/2025 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time